Enzychem Lifesciences KRX:183490KOSDAQ
엔지켐생명과학 · Korean news coverage and regulatory filings, organized.
Articles, 24h1
Articles, 7 days1
DART filings, 7 days1
Articles tracked9since Sep 11
In Q2 2026, Enzychem Lifesciences reported revenue of ₩23.5bn, up 43.5% year on year, and an operating loss of ₩4.1bn. Enzychem Lifesciences (엔지켐생명과학) appeared in 1 Korean news article and 1 DART filing over the past seven days. Coverage peaked on Oct 19 with 1 article.
Filing signals Revenue +30% 4 quarters of losses Litigation Share pledge Screener
Enzychem Lifesciences quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩23.5bn | +43.5% | −₩4.1bn margin −17.3% | −₩2.8bn |
| Q1 2026 | ₩14.9bn | -28.3% | −₩3.2bn margin −21.8% | −₩1.9bn |
| Q4 2025 derived | ₩14.1bn | -23.9% | −₩4.4bn margin −31.1% | −₩9.9bn |
| Q3 2025 | ₩16.5bn | -3.2% | −₩3.7bn margin −22.6% | −₩3.3bn |
| Q2 2025 | ₩16.4bn | -16.3% | −₩3.7bn margin −22.4% | −₩3.0bn |
| Q1 2025 | ₩20.8bn | -6.6% | −₩2.6bn margin −12.3% | −₩1.8bn |
| Q4 2024 derived | ₩18.5bn | -20.2% | −₩4.7bn margin −25.3% | −₩16.1bn |
| Q3 2024 | ₩17.0bn | -13.9% | −₩2.7bn margin −15.7% | −₩1.6bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Enzychem Lifesciences top stories 2 weeks, by number of outlets
- 1
- 2
Latest Enzychem Lifesciences news Korean headlines
-
엔지켐생명과학, 세계한상대회서 면역 건기식 록피드 해외 바이어와 접점 확대
1 more on this story · 1 outlets
- 엔지켐생명과학, 세계한상대회서 ‘록피드’ 해외 판로 확대 나서메디컬투데이 · Oct 1 13:53